

## About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated antibody products by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

### Our Strengths and Differentiators

- **World-class** antibody biology knowledge and deep insight into disease targets
- **Discovery and development** engine with proprietary technologies that allow us to build a world-class pipeline
- **In-house expertise** with solid track record of building successful strategic partnerships
- **Robust pipeline** of potential best-in-class and first-in-class therapies
- **Experienced**, diverse management team

### How we Operate



## At-a-glance

### Genmab's Growing Organization & Growing Presence

#### Princeton, USA

- Translational Research
- Development
- Commercial
- Corporate Functions

#### Tokyo, JP

- Clinical
- Commercial
- Corporate Functions

#### Utrecht, NL

- Research
- Translational Research
- Antibody Product Creation
- Corporate Functions

#### Copenhagen, DK

- HQ
- CMC Operations
- Clinical Operations
- Corporate Functions

### Operational


- 3 Approved Medicines in Collaboration**  
DARZALEX<sup>®</sup> marketed by Janssen Biotech Inc. in the U.S., Europe, Japan and multiple other countries. Kesimpta<sup>®</sup> marketed by Novartis in the U.S., TEPEZZA<sup>®</sup> marketed by Horizon Therapeutics in the U.S.
- 4 Proprietary Technologies**  
DuoBody<sup>®</sup> platform, HexaBody<sup>®</sup> platform, DuoHexaBody<sup>®</sup> platform & HexElect<sup>®</sup> platform
- 7 Proprietary\* Antibody Products in Clinical Development**  
Tisotumab vedotin, epcoritamab, DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042), HexaBody-DR5/DR5 (GEN1029), DuoHexaBody-CD37 (GEN3009) and DuoBody-CD3x5T4 (GEN1044)
- 15 Product Candidates Built on Genmab's Innovation**  
In clinical development with other companies and royalty streams for Genmab should they come to market.

\*Tisotumab vedotin 50:50 partnership with Seagen; epcoritamab, DuoHexaBody-CD37 and DuoBody-CD3x5T4 50:50 partnership with AbbVie; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB 50:50 partnership with BioNTech

### Financial

<b>DKK 161B</b> 2020 year-end market cap	<b>DKK 16,079M</b> 2020 year-end cash position
<b>DKK 10,111M</b> 2020 revenue 88% increase versus 2019	<b>DKK 3,798M</b> 2020 operating expenses 83% invested in R&D

### Operating Result (DKK million)



### Our Purpose

To improve the lives of patients with cancer by creating and developing innovative and differentiated antibody products

### Our Vision

By 2025, our own product has transformed cancer treatment, and we have a pipeline of knock-your-socks-off antibodies

### Our Values

- Passion for innovation
- Determined – being the best at what we do
- Integrity – we do the right thing
- We work as one team & respect each other

### Our Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable and successful biotech

# Strong Pipeline of 1st-in-class / Best-in-class Product Candidates



Genmab Proprietary <sup>1</sup> Products				Most Advanced Dev. Phase					
Product	Target	Developed by	Indications	Pre-clin.	I	I/II	II	III	Appr.
Tisotumab vedotin	TF	Co-developed Genmab/Seagen Inc.	Cervical cancer Ovarian cancer Solid tumors						BLA sub.
Epcoritamab	CD3, CD20	Co-developed Genmab/AbbVie Inc.	R/R DLBCL Hem. malign B-cell NHL (combo) R/R CLL						
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	Co-developed Genmab/BioNTech	Solid tumors						
DuoBody-CD40x4-1BB	CD40, 4-1BB	Co-developed Genmab/BioNTech	Solid tumors						
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors						
DuoHexaBody-CD37	CD37	Co-developed Genmab/AbbVie Inc.	Hem. malign.						
DuoBody-CD3x5T4	5T4	Co-developed Genmab/AbbVie Inc.	Solid tumors						
HexaBody-CD38	CD38	Genmab <sup>2</sup>	Hem. malign.						

Approved Medicines Created by Genmab <sup>3</sup>									
Daratumumab	CD38	Janssen	MM <sup>4</sup> AL Amyloidosis <sup>4</sup> Non-MM blood cancers						
Ofatumumab	CD20	Novartis	RMS <sup>4</sup>						
Teprotumumab	IGF-1R	Horizon	Thyroid eye disease <sup>4</sup> dcSSc						

Programs Incorporating Genmab's Innovation <sup>5</sup>									
Amivantamab	EGFR, cMet	Janssen	NSCLC						BLA sub.
Teclistamab	BCMA, CD3	Janssen	R/R MM						
Camidanlumab tesirine	CD25	ADC Therapeutics	R/R Hodgkin lymphoma Solid tumors						
PRV-015 (AMG 714)	IL-15	Provention Bio	Celiac disease						
Mim8	FIX(a), FX	Novo Nordisk	Hemophilia A						
Talquetamab	GPRC5D, CD3	Janssen	R/R MM						
JNJ-63709178	CD123, CD3	Janssen	AML						
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors						
JNJ-67571244	CD33, CD3	Janssen	R/R AML; MDS						
JNJ-70218902	Undisclosed	Janssen	Solid tumors						
HuMax-IL8	IL8	BMS	Adv. cancers						
Lu AF82422	alpha-synuclein	Lundbeck	Parkinson's						

## Proprietary Technologies Allow us to Build a World-class Pipeline

### DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

### HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

### DuoHexaBody Platform

- Antibody technology that combines
- DuoBody & HexaBody platforms
- Creates bispecific antibodies with target mediated enhanced potency

### HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

### Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO  
 Anthony Pagano, EVP & CFO  
 Judith Klimovsky M.D., EVP & CDO  
 Anthony Mancini, EVP & COO  
 Tahamtan Ahmadi, M.D., Ph.D., EVP & CMO, Head of Experimental Medicines

For more information/contact:  
[genmab.com](http://genmab.com) / [ir@genmab.com](mailto:ir@genmab.com)

<sup>1</sup>Certain product candidates in development with partners, as noted <sup>2</sup>Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc. <sup>3</sup>Products developed and marketed by others incorporating Genmab technology and innovation <sup>4</sup>See local country prescribing information for precise indications <sup>5</sup>Products under development by a third-party incorporating Genmab's technology and innovation.